Trials / Recruiting
RecruitingNCT06562231
Development of Isthmocele Symptom Severity and Quality of Life Scale
Development of Isthmocele Symptom Severity and Quality of Life Questionnaire
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 330 (estimated)
- Sponsor
- Hilal Yuvacı · Academic / Other
- Sex
- Female
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Not accepted
Summary
Isthmocele, also known as cesarean scar defect (CSD), is the disruption of the integrity of the myometrium in the cesarean section incision and the indentation of the opening in the myometrium towards the visceral peritoneum. Residual menstrual blood accumulating in the isthmocele sac can cause chronic endometritis, anormal uterine bleeding, infertility and chronic pelvic pain. There is currently no quality of life scale that assesses isthmocele symptoms. A scale is needed to determine the positive effect on the patient's quality of life after the surgeries are performed. This study it is aimed to develop a scale that evaluates the severity of isthmocele symptoms and the impact on quality of life due to isthmocele.
Detailed description
Patients with isthmocele symptoms three months after cesarean delivery will be included in the study.The study will not include findings that may be confused with isthmocele symptoms, such as uterine fibroids and endometrial polyps. Patients with acute vaginitis and pelvic inflammatory disease will not be included in the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | quality of life scale | This study will be conducted on women diagnosed with symptomatic isthmocele after cesarean section. Researchers will prepare scale questions, and the survey questions will be developed after obtaining an expert opinion from 20 experts to be evaluated by psychiatry, obstetrics, and public health experts. The patient will fill out the questionnaire form with the diagnosis of isthmocele. Oral and written consent will be obtained from the patients. |
Timeline
- Start date
- 2023-01-01
- Primary completion
- 2025-06-01
- Completion
- 2025-12-30
- First posted
- 2024-08-20
- Last updated
- 2024-08-20
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT06562231. Inclusion in this directory is not an endorsement.